Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates

Dare Bioscience reported a +91.67% earnings surprise and a -28.41% revenue surprise for the quarter ended December 2025. The combination of a large EPS beat with a sizable top‑line miss points to one‑time items, cost control or recognition timing rather than clear revenue-driven growth. Expect near-term share volatility as investors seek management commentary and forward guidance to assess sustainability.

Analysis

Dare Bioscience reported a +91.67% earnings surprise and a -28.41% revenue surprise for the quarter ended December 2025. The combination of a large EPS beat with a sizable top‑line miss points to one‑time items, cost control or recognition timing rather than clear revenue-driven growth. Expect near-term share volatility as investors seek management commentary and forward guidance to assess sustainability.